[PDF][PDF] Bexarotene and erlotinib for aerodigestive tract cancer
KH Dragnev, WJ Petty, S Shah, A Biddle… - Journal of clinical …, 2005 - researchgate.net
Journal of clinical oncology, 2005•researchgate.net
Purpose The epidermal growth factor receptor (EGFR) and cyclin D1 are overexpressed in
lung carcinogenesis. The rexinoid, bexarotene, represses cyclin D1 and EGFR expression
in vitro. It was hypothesized that combining bexarotene with the EGFR inhibitor, erlotinib,
would augment clinical activity.
lung carcinogenesis. The rexinoid, bexarotene, represses cyclin D1 and EGFR expression
in vitro. It was hypothesized that combining bexarotene with the EGFR inhibitor, erlotinib,
would augment clinical activity.
Purpose
The epidermal growth factor receptor (EGFR) and cyclin D1 are overexpressed in lung carcinogenesis. The rexinoid, bexarotene, represses cyclin D1 and EGFR expression in vitro. It was hypothesized that combining bexarotene with the EGFR inhibitor, erlotinib, would augment clinical activity.
researchgate.net